Drug Trial Radar · NCT04456296
A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism
Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
673
Actual
Start
Jun 30, 2020
Primary completion
Jul 12, 2023
Study completion Jul 12, 2023
Sponsor
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics CompanyIndustry
- Sponsor type
- Industry
- First posted
- Jul 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Testosterone is the principal androgen produced by the male testes. Male Hypogonadism is the result of inadequate production of testosterone by the Leydig cells of the testes and is reflected by total serum concentrations of testosterone of \< 300 nanograms (ng)/deciliters (dL), with no discernible diurnal pattern. The etiology of hypogonadism may be primary or secondary. The treatment of males with primary, and in some cases, secondary hypogonadism includes administration of testosterone. Testim® and Fortesta® are topical gels that when applied daily help to increase the total testosterone levels in the blood through skin absorption. Aveed® is an injectable form of testosterone treatment and participants randomized to this treatment arm will receive 3 injections over the course of 16 weeks. This study is designed to evaluate the effect on blood pressure of approved testosterone products (Testim®, Fortesta®, and Aveed®) after 16 weeks of therapy using 24-hour ambulatory blood pressure to reveal shifts in blood pressure levels.
Conditions
- Hypogonadism
- Hypogonadism, Male
- Hypogonadotropic Hypogonadism
Interventions
Aveed Injectable ProductDrug
Testosterone undecanoate administered by intramuscular injections.
FortestaDrug
Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
TestimDrug
Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in 24-Hour Average Systolic Ambulatory Blood Pressure to End of Study (EOS)Time frame: Baseline (Day 1), EOS Visit: up to Day 107 for the Aveed Arm, and up to Day 114 for Fortesta and Testim Arms
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Endo Clinical Trial Site #8
Birmingham, Alabama
Endo Clinical Trial Site #22
Tucson, Arizona
Endo Clinical Trial Site #15
North Little Rock, Arkansas
Endo Clinical Trial Site #32
Bell Gardens, California
Endo Clinical Trial Site #33
Canoga Park, California
Endo Clinical Trial Site #30
Beverly Hills, Florida
Endo Clinical Trial Site #12
Boynton Beach, Florida
Endo Clinical Trial Site #34
Boynton Beach, Florida
Endo Clinical Trial Site #29
Fleming Island, Florida
Endo Clinical Trial Site #26
Miami, Florida
Endo Clinical Trial Site #2
Miami, Florida
Endo Clinical Trial Site #28
Miami, Florida
Endo Clinical Trial Site #10
Miami Beach, Florida
Endo Clinical Trial Site #18
Miami Gardens, Florida
Endo Clinical Trial Site #3
Oviedo, Florida
Endo Clinical Trial Site #4
Pembroke Pines, Florida
Endo Clinical Trial Site #11
Pompano Beach, Florida
Endo Clinical Trial Site #23
West Palm Beach, Florida
Endo Clinical Trial Site #16
Chicago, Illinois
Endo Clinical Trial Site #27
Glen Burnie, Maryland
Endo Clinical Trial Site #17
Towson, Maryland
Endo Clinical Trial Site #35
East Orange, New Jersey
Endo Clinical Trial Site #9
Garden City, New York
Endo Clinical Trial Site #7
New York, New York
Endo Clinical Trial Site #25
Winston-Salem, North Carolina
Endo Clinical Trial Site #5
Dayton, Ohio
Endo Clinical Trial Site #13
Bala-Cynwyd, Pennsylvania
Endo Clinical Trial Site #19
Houston, Texas
Endo Clinical Trial Site #31
Houston, Texas
Endo Clinical Trial Site #20
Houston, Texas
Endo Clinical Trial Site #21
Missouri City, Texas
Endo Clinical Trial Site #1
San Antonio, Texas
Endo Clinical Trial Site #14
Rutland, Vermont
Endo Clinical Trial Site #6
Charlottesville, Virginia
Endo Clinical Trial Site #24
Virginia Beach, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.